Ganoderenic acid KCAS# 942950-94-9 |
Quality Control & MSDS
Package In Stock
Number of papers citing our products
| Cas No. | 942950-94-9 | SDF | Download SDF |
| PubChem ID | N/A | Appearance | Powder |
| Formula | C32H44O9 | M.Wt | 572.7 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Ganoderenic acid K Dilution Calculator
Ganoderenic acid K Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7461 mL | 8.7306 mL | 17.4611 mL | 34.9223 mL | 43.6529 mL |
| 5 mM | 0.3492 mL | 1.7461 mL | 3.4922 mL | 6.9845 mL | 8.7306 mL |
| 10 mM | 0.1746 mL | 0.8731 mL | 1.7461 mL | 3.4922 mL | 4.3653 mL |
| 50 mM | 0.0349 mL | 0.1746 mL | 0.3492 mL | 0.6984 mL | 0.8731 mL |
| 100 mM | 0.0175 mL | 0.0873 mL | 0.1746 mL | 0.3492 mL | 0.4365 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Gardoside methyl ester
Catalog No.:BCN0832
CAS No.:93930-20-2
- Oxytroflavoside A
Catalog No.:BCN0831
CAS No.:1391144-80-1
- 12beta-Acetoxy-3beta-hydroxy-7,11,15,23-tetraoxo-lanost-8,20-diene-26-oic acid
Catalog No.:BCN0830
CAS No.:1085338-75-5
- Oxytroflavoside E
Catalog No.:BCN0829
CAS No.:1391144-84-5
- Pinocembrin 7-O-(4'',6''-hexahydroxydiphenoyl)-beta-D-glucose
Catalog No.:BCN0828
CAS No.:1825287-22-6
- Cannabisin P
Catalog No.:BCN0827
CAS No.:2756983-19-2
- Oblonganoside D
Catalog No.:BCN0826
CAS No.:943021-91-8
- 10-Carboxyloganin
Catalog No.:BCN0825
CAS No.:182172-02-7
- Gambogic acid A
Catalog No.:BCN0824
CAS No.:1592842-93-7
- 10-Hydroxyaloin B
Catalog No.:BCN0823
CAS No.:134863-92-6
- 10-Methoxygambogenic acid
Catalog No.:BCN0822
CAS No.:2095102-72-8
- 3beta-Hydroxyurs-12,18-dien-28-oic acid beta-D-glucopyranosyl ester
Catalog No.:BCN0821
CAS No.:434942-42-4
- 2,6-Dihydroxyacetophenone-4-O-[4',6'-(S)-hexahydroxydiphenoyl]-beta-D-glucose
Catalog No.:BCN0834
CAS No.:1781226-44-5
- Ganolucidic acid D
Catalog No.:BCN0835
CAS No.:102607-22-7
- Rhamnocitrin 3-galactoside
Catalog No.:BCN0836
CAS No.:99878-05-4
- Otobaphenol
Catalog No.:BCN0837
CAS No.:10240-16-1
- 8-Epiloganin
Catalog No.:BCN0838
CAS No.:79172-04-6
- Isosecotanapartholide
Catalog No.:BCN0839
CAS No.:102926-01-2
- Malabaricone C
Catalog No.:BCN0840
CAS No.:63335-25-1
- Baishouwubenzophenone
Catalog No.:BCN0841
CAS No.:115834-34-9
- Malabaricone A
Catalog No.:BCN0842
CAS No.:63335-23-9
- Silybin A
Catalog No.:BCN0843
CAS No.:36804-17-8
- 4-p-Menthan-1,8-diol
Catalog No.:BCN0844
CAS No.:565-48-0
- Neomogroside
Catalog No.:BCN0845
CAS No.:189307-15-1
Triterpenes and meroterpenes from Ganoderma lucidum with inhibitory activity against HMGs reductase, aldose reductase and alpha-glucosidase.[Pubmed:28527898]
Fitoterapia. 2017 Jul;120:6-16.
Seven new compounds including four lanostane triterpenoids, lucidenic acids Q-S (1-3) and methyl ganoderate P (4), and three triterpene-farnesyl hydroquinone conjugates, ganolucinins A-C (5-7), one new natural product ganomycin J (8), and 73 known compounds (9-81) were isolated from fruiting bodies of Ganoderma lucidum. The structures of the compounds 1-8 were determined by spectroscopic methods. Bioactivities of compounds isolated were assayed against HMG-CoA reductase, aldose reductase, alpha-glucosidase, and PTP1B. Ganolucidic acid eta (39), Ganoderenic acid K (44), ganomycin J (8), and ganomycin B (61) showed strong inhibitory activity against HMG-CoA reductase with IC50 of 29.8, 16.5, 30.3 and 14.3muM, respectively. Lucidumol A (67) had relatively good effect against aldose reductase with IC50 of 19.1muM. Farnesyl hydroquinones ganomycin J (8), ganomycin B (61), ganomycin I (62), and triterpene-farnesyl hydroquinone conjugates ganoleuconin M (76) and ganoleuconin O (79) possessed good inhibitory activity against alpha-glucosidase with IC50 in the range of 7.8 to 21.5muM. This work provides chemical and biological evidence for the usage of extracts of G. lucidum as herbal medicine and food supplements for the control of hyperglycemic and hyperlipidemic symptoms.
